Navigation Links
WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
Date:7/20/2009

SHANGHAI, July 20 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2009 after the New York Stock Exchange closes on Tuesday, August 11, 2009 (which will be Wednesday morning, August 12, 2009 Shanghai time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations section of its website at http://www.wuxiapptec.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Wednesday, August 12, 2009, to discuss the second-quarter 2009 financial results and recent business activities. The conference call may be accessed by calling:

        United States: 1-866-519-4004
        China (Landline): 800-819-0121
        China (Mobile): 400-620-8038
        Hong Kong: 800-933-053
        United Kingdom: 0-808-234-6646
        International: +65-6735-7955
        Conference ID: 19244798
        Web PIN: 8656

    A telephone replay will be available two hours after the call's completion
at:

        United States: 1-866-214-5335
        China North: 10-800-714-0386
        China South: 10-800-140-0386
        Hong Kong: 800-901-596
        United Kingdom: 0-800-731-7846
        International: +61-2-8235-5000
        Conference ID # 19244798

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Receives Award from BASF
2. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
3. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
4. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
5. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
6. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
7. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
10. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
11. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
(Date:2/8/2016)... 8, 2016 Should antibiotic bone cement products ... to prevent infection after standard total hip or knee ... ECRI Institute have been fielding a lot lately. ... Bottom Line?" --> "Antibiotic Bone ... --> While there isn,t a simple ...
(Date:2/8/2016)... 2016 --> ... innovation-driven oncology company developing next generation cancer therapeutics ... announced that chairman emeritus of Tata Sons Limited, ... company as part of the first close of ... Navam Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas J. Todorow has joined ... President for Corporate Services and the Chief Financial Officer at The Children’s Hospital ... Treasury, Managed Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP ...
Breaking Biology Technology:
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):